PLANO, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, Diron Smith, Vice President and Interim Chief Financial Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development & Investor Relations, are scheduled to participate at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 1:30 p.m. ET.
A live webcast of the presentation will be available through Integer’s investor relations website at investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: | |
| Andrew Senn | Kelly Butler | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$119.54 |
| Daily Change: | -0.42 -0.35 |
| Daily Volume: | 99,605 |
| Market Cap: | US$4.170B |
July 10, 2025 April 24, 2025 April 24, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
